Identifying Genetic Disorders and Implementing Genetic Testing for the Wisconsin Plain Community



Ashley Kuhl*², Kristy Lee*^{1,2}, Britainney A. Petrie¹, Christopher N. Vlangos⁵, Christine M. Seroogy², Gregory M. Rice², Jim DeLine⁴, Thomas Herr⁴, Danielle Elsberry¹, Maureen McCormack¹, Leah Frater-Rubsam¹, Vanessa L. Horner^{1,3}, Jennifer J. Laffin^{1,2,3}, Jessica A. Scott-Schwoerer²

Clinical Genetics Laboratories, Wisconsin State Laboratory of Hygiene, Madison, WI¹ Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI³ Department of Pathology and Molecular Diagnostics Laboratory, Virginia Commonwealth University, Richmond, VA⁵ * Co-First Authors

Department of Pediatrics, University of Wisconsin-Madison, Madison, WI² La Farge Medical Clinic-Vernon Memorial Healthcare, La Farge, WI⁴


PURPOSE

To develop an accessible, low cost genetic testing infrastructure to identify genetic disorders in Wisconsin Plain communities.

BACKGROUND

Wisconsin has the fourth largest Plain population in the United States with an estimated 17,000 Old Order Amish and 2,500 Old Order Mennonites and the population continues to have rapid growth. These isolated communities are subject to founder effects resulting in a higher frequency of autosomal recessive genetic disorders.

Members of the Plain communities have limited access to specialized health care due to lack of insurance, difficulties with travel, and the unavailability of local physicians with experience in identifying genetic disorders.



METHODS

Families were counseled and consented for genetic testing at:

- the La Farge Medical Clinic,
- the University of Wisconsin Genetics Clinic or within their homes.



Three approaches were used to identify pathogenic variants for a variety of disorders in the population:

1. Targeted Variant Sequence Analysis (TVAR)


for identification of characterized pathogenic variants associated with known genotype/phenotype correlations segregating within the Plain population

2. Single Nucleotide Polymorphism (SNP) microarrays

to identify recurrent genomic dosage aberrations and regions of homozygosity that may indicate disease associated genes or variants

3. Whole Exome Sequencing (WES)

to identify novel and characterized variants within the protein-coding regions of genes.



RESULTS								
Conditions Prevalent in Plain Population - with Classic Presentation								
Condition Identified	Presenting Symptoms/ Family History	Test	Gene	Mutation/ Inheritance	Pathophysiology	Classic presentation	Treatment/ Prognosis	
Galloway-Mowat syndrome	Sibs (2 year old and 4 month old) with global developmental delay (GDD), failure to thrive (FTT), microcephaly, spasticity, abnormal movements and nystagmus. Older child had proteinuria. 3 paternal aunts with GDD; 2 died from kidney failure in childhood. Parents are 2 nd cousins.	TVAR	WDR73	Homozygous for: c.888delT p.Phe296Leufs*26 Autosomal Recessive (AR)	Neurodegenerative disorder caused by dysfunction of the WDR73 protein expressed in brain and kidney tissues.	Progressive microcephaly, visual impairment with nystagmus, stagnant psychomotor development, intellectual disability (ID), abnormal extrapyramidal movements, cerebellar atrophy, and steroid non-responsive nephrosis. Life limiting due to kidney failure.	Symptomatic care. Typically life limiting due to kidney failure.	
Infantile Lethal Cardiomyopathy	Tana moaerale muscular V XII. Bamily decline transniant	TVAR	MYBPC3	Homozygous for: c.3330+2T>G p.Asp1064Glyfs*38 AR ^a	Dysfunction of myosin binding protein C results in severe hypertrophic cardiomyopathy.	Infantile onset cardiomyopathy resulting in heart failure and death within 3 to 4 months without transplant. Strongly suspected carriers are at risk for hypertrophic cardiomyopathy.	Heart transplantation or palliative care.	
Cobalamin C Deficiency	2 week old with abnormal newborn screen - elevated C3. Had elevated methylmalonic acid (MMA) and homocysteine (HCY). Propionic acidemia(PA) testing was normal.	TVAR	MMACHC	Homozygous for: c.271dupA p.Arg91Lysfs*14 ^b AR	Dysfunction of the MMACHC enzyme responsible for cobalamin trafficking resulting in decreased methionine and increased MMA and HCY levels.	Intrauterine growth retardation, microcephaly, congenital heart disease, poor feeding, lethargy, failure to thrive, hypotonia, seizures, nystagmus and GDD.	Betaine, carnitine and intramuscular B12 as well as fasting and illness precautions.	
Sitosterolemia	9 year old with xanthomas on hands, knee and Achilles tendon, short stature, and failure to gain weight.	TVAR	ABCG8	Homozygous for: c.1720G>A p.Gly574Arg AR	Dysfunction of sterolin, a protein responsible for eliminating plant sterols that cannot be used by human cells.	Xanthomas, premature atherosclerosis, hemolytic anemia and thrombocytopenia.	Medication (Ezetimibe) and specialized diet to reduce sterol levels.	
Propionic Acidemia	7 year old with complicated post-natal course including pulmonary hypertension. Continued to have seizures and developmental delays. Abnormal newborn screen during this evaluation.	TVAR	РССВ	Homozygous for: c.1606A>G p.Asn536Asp AR	Deficiency of the beta subunit of propionyl-CoA-carboxylase, which results in an accumulation of propionic acid and associated metabolites.		Patient started on specialized diet and given illness precautions.	
			Condition	ns Prevalent in Plain	Population - with Non-traditional Preser	ntation		
Condition Identified	Presenting Symptoms/ Family History	Test	Gene	Mutation/ Inheritance	Pathophysiology	Classic presentation	Treatment/ Prognosis	
Cortical Dysplasio Focal Epilepsy syndrome		aCGH, then TVAR	CNTNAP2	Homozygous for: c.3709delG p.Asp1237Ilefs*17 AR	Dysfunction of a protein important for nervous system development and function.	Seizures, DD, regression in language and social skills, ID, cortical dysplasia, and behavioral concerns (hyperactivity or impulsive aggression).	Symptomatic care.	
Symptomatic Epilepsy and Skul Dysplasia	24 year old with profound ID, ptosis, robust stature, and well-controlled seizures. Walked with limited assistance.		SNIP1	Homozygous for: c. 1097A>G p.Glu366Gly AR	Dysfunction of SNIP1 protein, likely involved in signal transduction cascade for brain, skull, craniofacial bones and distal limbs.	Severe DD with inability to walk or speak, hypotonia with poor feeding in infancy, brain abnormalities, intractable seizures, dysmorphic facial features and a "lumpy" skull surface.	Symptomatic care.	
Mucolipidosis Type II (I-cell disease)	Amish 2 year old with coarse facial features, FTT, poor growth, small thoracic cavity, profound DD, respiratory distress and infections, dilated cardiomyopathy and dysplastic cardiac valves. Normal berry spot and alpha-L-Iduronidase enzyme testing. Child died at age 3.	then	GNPTAR	Homozygous for: c.3503-3504delC ^c AR	Dysfunction of lysosomal enzyme (GlcNAc-1-phosphotransferase) resulting in accumulation of carbohydrates and lipids and cell damage.	Hypotonia, weak cry, poor growth, multiple bone abnormalities with dysostosis multiplex, heart valve abnormalities, coarse facial features, GDD and narrow airway which leads to respiratory concerns. Children usually die in early childhood. Previously seen in two Mennonite children, but no Amish patients.	Symptomatic care.	
	Conditions Not Thought to be More Prevalent in Plain Population							
Condition Identified	Presenting Symptoms/ Family History	Test	Gene	Mutation/ Inheritance	Pathophysiology	Classic presentation	Treatment/ Prognosis	
Rett syndrome	17 year old with central hand wringing, developmental regression at 18 mos., severe ID, febrile seizures, laughing fits, breath holding spells, and growth retardation. Teacher suspected Rett syndrome.	specific gene	MECP2	Heterozygous for: partial exon 4 deletion X-linked Dominant	Altered expression of MECP2 important for nervous system development and function.	Developmental regression, especially in the areas of communication and coordination, around age 6 to 18 months, loss of purposeful hand movements in early childhood, microcephaly, breathing abnormalities, seizures, scoliosis and sleep disturbances.		
16p11.2 duplication syndrome	19 year old with mild to moderate ID, childhood seizures, nonverbal until age 8, mildly dysmorphic facial features. AGA at birth. No concerns for growth, behavior or social concerns. Negative Fragile X testing.	aCGH		Heterozygous for duplication Autosomal Dominant (AD)		Variable presentation that include ID, DD - particularly speech, autism, ADHD, and mental health disorders. Recurrent seizures and poor growth have also been reported. Some people with this duplication have no health or developmental concerns.	Symptomatic care.	
Ataxia Telangiectasia - Like Type 2	4 year old who was small for gestational age, poor growth (ht and wt < -3 SD), ataxia, GDD, and nonverbal until age 4. Clinical diagnosis of spastic paraplegia. Physical exam: hairline scarring, irregular pigmentation and freckles at temples bilaterally. No telangiectasias.	WES	PCNA	Homozygous for: c. 683G>T p.Ser228Ile AR	Neurodegenerative disorder due to defects in DNA excision repair.	Short stature (-3.8 to -5.2 SD), ataxia, DD, telangiectasias	Symptomatic care.	

Homozygous for:

c.1213_1276del

p.Lys405Leufs*12

IQCB1

CONCLUSION

Collectively, we have provided diagnostic testing and diseasespecific education and counseling in an accessible manner to the Plain communities of Wisconsin.

Through this process, we have increased our knowledge about

• the presence of specific disorders within the WI Plain population, and

18 year old with progressively poor vision since early

childhood. Eye exam showed retinal dystrophy with rod

and cone dysfunction - Retinitis Pigmentosa v. Leber

Congenital Amaurosis. No other health concerns.

Normal renal function tests.

Many relatives with poor vision. Parents are 2ndcousins.

^b - Associated with severe, early-onset disease. Accounts for 40% of all disease-causing alleles.

- Carriers may be symptomatic, which would be associated with AD inheritance.

Senior-Loken

syndrome Type 5

• the phenotypic spectrum of these conditions.

We have also developed and validated several affordable clinically available TVAR tests for this population.

Altogether, this ultimately improves detection of and the medical management for these previously undiagnosed genetic disorders.

REFERENCES

Retinal dystrophy and nephronophthisis with ocular onset in infancy

to early childhood. Renal symptoms have variable onset and, when

present, progress to end stage renal disease.

Symptomatic care.

Donnermeyer, Joseph F., and David Luthy. 2013. "Amish Settlements across America: 2013." Journal of Amish and Plain Anabaptist Studies

d – Immunodeficiency can be seen in ataxia telangiectasia caused by ATM mutations (more common in Amish and Mennonite populations.

- 2. Jinks RN et al. 2015. "Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-
- truncating mutations of WDR73." Brain 138(Pt8):2173-90. Vodopiutz J et al. 2015. "WDR73 Mutations Cause Infantile Neurodegeneration and Variable Glomerular Kidney Disease." Hum Mutat.
- Colin E et al. 2014. "Loss-of-function mutations in WDR73 are responsible for microcephaly and steroid-resistant nephrotic syndrome:
- Galloway-Mowat syndrome." Am J Hum Genet 95(6):637-48). Xin B et al. 2007. "Homozygosity for a novel splice site mutation in the cardiac myosin-binding protein C gene causes severe neonatal
- hypertrophic cardiomyopathy." Am J Med Genet 143A(22):266-7.
- Zahka K et al. 2008. "Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish." Heart 94(10):1326-30.
- Carrillo-Carrasco N et al. 2012. "Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and
- management." J Inherit Metab Dis 35(1)91-102. 8. Fischer S et al. 2014. "Clinical presentation and outcome in a series of 88 patients with the cblC defect." J inherit Metab Dis 37(5):831-10.
- Merkens Louise et al. 2013. "Sitosterolemia" GeneReviews

10. Puffenberger Eric G et al. 2012. "Genetic Mapping and Exome Sequencing Identify Variants Associated with Five Novel Diseases" PLOS One

- DOI: 10.1371
- 11. Plante M et al. 2008. "Mucolipidosis II: a single causal mutation in the N-acetylglucosamine-1-phosphotransferase gene (GNPTAB) in a
- French Canadian founder population" Clin Genet 73:236-44.
- 12. Christodoulou, John and Ho, Gladys. 2001. "MECP2-Related Disorders" GeneReviews.
- 13. Miller, David T et al. 2009. "16p11.2 Recurrent Microdeletion" GeneReviews.
- 14. Baple E et al. 2014. "Hypomorphic PCNA mutation underlies a human DNA repair disorder" J Clin Invest. 124(7):3137-46.
- 15. O'Neill, Marla. 2012. "Senior-Loken Syndrome 5" OMIM.

Interacts with calmodulin and may

participate in common pathway of ciliary

function

^c - Common French Canadian mutation